DNA Test Launched for Laser Eye Surgery Safety
|
By LabMedica International staff writers Posted on 27 May 2014 |

Image: Granular corneal dystrophy (Photo courtesy of Dr. B.H. Feldman).
A genetic test has been introduced that can detect both Avellino Corneal Dystrophy (ACD) and another genetic mutation, Granular Corneal Dystrophy type I (GCD1).
A patient with GCD1 who undergoes vision correction surgery, such as Laser-Assisted in situ Keratomileusis (LASIK), Laser-Assisted Sub-Epithelial Keratectomy (LASEK) or Photorefractive keratectomy (PRK) are at extreme risk of experiencing eventual blindness.
The Avellino DNA Dual Test (Avellino Laboratory; Menlo Park, CA, USA) is able to detect the presence of the genetic mutation, allowing the patient to take precautionary steps to postpone the progression of the condition, including avoiding vision correction surgery. The Avellino DNA Dual Test is easy and safe. The test involves a simple mouth swab to determine whether a person carries the GCD1 or the GCD2 (ACD) gene mutation. Specifically, the ophthalmologist takes 10 swipes from the inside of each cheek in order to obtain an adequate sample. The sample is then sent to Avellino Lab USA, a Clinical Laboratory Improvement Amendments (CLIA) certified molecular diagnostic testing laboratory. Within 24 to 48 hours, the results are provided to the physician to share with the patient. Avellino Laboratory has branches in North America, Western Europe, and Asia.
Granular Corneal Dystrophy (type 1 and 2) has been diagnosed in patients throughout the world and is one of the more well-known corneal dystrophies related to genetic mutations. Unfortunately, many physicians assume incorrectly that they can diagnose the condition through a visual examination and family history. However, many patients do not show physical symptoms of the condition until later in life. Consequently, relying solely on traditional methods for diagnosis can put patients at risk.
Tom Tooma, MD, founder of NVISION Laser Eye Center, said, (Newport Beach, CA, USA) said, “We have been utilizing the Avellino DNA Test for LASIK Safety since its availability in the United States, and it has been a fantastic tool for both our physicians and patients in increasing their confidence prior to LASIK. Now, with the Avellino DNA Dual Test, patients can go into treatment knowing they are even more protected from adverse outcomes such as loss of vision.” The Avellino DNA Test for LASIK Safety has become the standard of care in Korea with 160 LASIK clinics using this test and in Japan more than 80% of LASIK patients were tested.
Related Links:
Avellino Laboratory
NVISION Laser Eye Center
A patient with GCD1 who undergoes vision correction surgery, such as Laser-Assisted in situ Keratomileusis (LASIK), Laser-Assisted Sub-Epithelial Keratectomy (LASEK) or Photorefractive keratectomy (PRK) are at extreme risk of experiencing eventual blindness.
The Avellino DNA Dual Test (Avellino Laboratory; Menlo Park, CA, USA) is able to detect the presence of the genetic mutation, allowing the patient to take precautionary steps to postpone the progression of the condition, including avoiding vision correction surgery. The Avellino DNA Dual Test is easy and safe. The test involves a simple mouth swab to determine whether a person carries the GCD1 or the GCD2 (ACD) gene mutation. Specifically, the ophthalmologist takes 10 swipes from the inside of each cheek in order to obtain an adequate sample. The sample is then sent to Avellino Lab USA, a Clinical Laboratory Improvement Amendments (CLIA) certified molecular diagnostic testing laboratory. Within 24 to 48 hours, the results are provided to the physician to share with the patient. Avellino Laboratory has branches in North America, Western Europe, and Asia.
Granular Corneal Dystrophy (type 1 and 2) has been diagnosed in patients throughout the world and is one of the more well-known corneal dystrophies related to genetic mutations. Unfortunately, many physicians assume incorrectly that they can diagnose the condition through a visual examination and family history. However, many patients do not show physical symptoms of the condition until later in life. Consequently, relying solely on traditional methods for diagnosis can put patients at risk.
Tom Tooma, MD, founder of NVISION Laser Eye Center, said, (Newport Beach, CA, USA) said, “We have been utilizing the Avellino DNA Test for LASIK Safety since its availability in the United States, and it has been a fantastic tool for both our physicians and patients in increasing their confidence prior to LASIK. Now, with the Avellino DNA Dual Test, patients can go into treatment knowing they are even more protected from adverse outcomes such as loss of vision.” The Avellino DNA Test for LASIK Safety has become the standard of care in Korea with 160 LASIK clinics using this test and in Japan more than 80% of LASIK patients were tested.
Related Links:
Avellino Laboratory
NVISION Laser Eye Center
Latest Molecular Diagnostics News
- Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary
- Blood Test Enables Early Detection and Classification of Glioma
- Multi-Biomarker Blood Test Detects Early-Stage Cancers Across Types
- New Sample-to-Answer PCR System Supports High-Throughput Infectious Disease Testing
- Framework Guides Targeted Immunotherapy Selection in Liver Cancer
- Collaboration Brings Rapid At-Home STI Testing with Virtual Follow-Up
- Blood-Based Epigenetic Signals Enable Osteosarcoma Disease Monitoring
- Host–Virus Genetic Interactions Drive Nasopharyngeal Cancer Risk
- AI-Enabled Biochip Detects microRNA Biomarkers in Minutes
- Blood Test Detects Early Pancreatic Cancer in High-Risk Patients
- Long-Read RNA Sequencing Platform Improves Rare Disease Diagnosis
- Study Confirms Barrett’s Esophagus as Precursor to Esophageal Cancer
- Ultrasensitive Assay Reveals Previously Undetected Tuberculosis in Hospital Patients
- CE-Marked Blood Test Enables Monitoring of Neuroinflammation in Multiple Sclerosis
- Urine-Based Assay Predicts Severe Dengue Risk Early
- Ultrasensitive Assay Tracks Resistance Mutations MRD Monitoring
Channels
Clinical Chemistry
view channel
Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation
Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more
Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms
Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read moreHematology
view channel
Routine Blood Test Parameters Link Anemia to Cancer Risk and Mortality
Anemia detected in routine care can signal underlying pathology and is frequently encountered in adults. Because it is defined by hemoglobin levels below the normal range, it is often evaluated with red... Read more
Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer
Chronic myelomonocytic leukemia (CMML) is a rare blood cancer in which acquired genetic mutations in bone marrow stem cells drive disease. Stem cell transplantation is the only curative option but carries... Read moreImmunology
view channel
Immune Aging Clock Quantifies Immunosenescence and Identifies Therapeutic Target
Immune aging undermines host defense and contributes to multiple age-related diseases, yet its heterogeneity complicates measurement and intervention. Clinical laboratories increasingly seek objective... Read more
Study Finds Influenza Often Undiagnosed in Winter Deaths
Seasonal influenza drives substantial excess mortality, yet its contribution is often obscured when infections go undiagnosed near the time of death. Many deaths occur outside hospitals or in older adults... Read moreMicrobiology
view channel
Rapid Blood-Culture Susceptibility Panel Expands Coverage for Gram-Negative Infections
Gram-negative bloodstream infections and sepsis demand fast, precise antimicrobial therapy, yet conventional susceptibility workflows can delay targeted treatment. Clinical laboratories need platforms... Read more
Antibiotic Resistance Genes Found in Newborns Within Hours of Birth
Antibiotic resistance in early life is challenging to characterize, particularly around the timing and drivers of gene acquisition in newborns. Meconium, the first stool passed by infants, was long considered... Read morePathology
view channel
AI Precision Tests Deliver Cancer Risk Insights from Routine H&E Slides
Reliable prognostic profiling and biomarker screening are essential to guide oncology treatment decisions, while laboratories must balance speed and resource constraints. Earlier identification of high‑risk... Read more
Study Reveals Moleclar Mechanism Driving Aggressive Skin Cancer
Cutaneous squamous cell carcinoma (cSCC) is the world’s second most common skin cancer, and while many cases are treatable, a subset becomes highly aggressive and therapy‑resistant. Identifying molecular... Read moreTechnology
view channel
AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
Advanced bowel cancer remains difficult to treat, and many patients receive targeted therapies that do not help them but still cause harm. Clinicians need reliable ways to identify likely responders before... Read more
Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
Pre-analytical variation remains a leading source of inconsistent molecular test results and added costs, particularly when laboratories rely on multiple instruments and protocols. Standardizing nucleic... Read moreIndustry
view channel
QuidelOrtho Adds Ultra-Fast PCR Platform with LEX Acquisition
QuidelOrtho Corporation has completed the acquisition of LEX Diagnostics for approximately USD 100 million in cash. The transaction adds the LEX VELO System to QuidelOrtho’s portfolio. The platform received U.... Read more
Seegene Showcases Real-Time PCR Data Analytics Platform at ESCMID
Seegene introduced STAgora, a real-time data analytics platform built on aggregated statistical testing data, at ESCMID Global 2026 in Munich, where it also presented an enhanced model of its automated... Read more
Roche Affiliate Expands MRD Portfolio with SAGA Acquisition
Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more







